Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint

Compass Pathways' Phase 3 trial for its psilocybin treatment, COMP360, in treatment-resistant depression met its primary endpoint, demonstrating a statistically significant 3.6-point reduction in MADRS scores at week 6 compared to placebo. Despite the positive clinical outcome and no unexpected safety issues, CMPS shares plunged almost 45% as investors had anticipated a larger 5-6 point reduction. The company plans to discuss these results with the FDA and continue a second Phase 3 trial, with longer-term data expected in late 2026.

Analysis

Compass Pathways (CMPS) reported a paradoxical outcome from its Phase 3 trial for its psilocybin formulation, COMP360, in treating treatment-resistant depression. While the trial successfully met its primary endpoint by demonstrating a statistically significant 3.6-point mean reduction on the MADRS depression scale compared to placebo at week 6, the result failed to meet heightened investor expectations. The market, which had anticipated a more pronounced efficacy signal in the 5-to-6-point range, reacted severely, sending the company's shares down nearly 45% to approximately $2.50. This disconnect highlights a significant expectations miss despite the clinical validation. On a positive note for the drug's profile, an independent safety board reported no new safety concerns. However, the path forward involves further regulatory engagement with the FDA and a second Phase 3 trial, with longer-term data not anticipated until late 2026, extending the timeline for potential commercialization.

Key Decisions for Investors

• Investors should acknowledge the significant disconnect between the trial's clinical success and the market's negative reaction, anticipating continued stock volatility driven by revised efficacy expectations rather than the binary trial outcome.
• The path to potential approval is now extended, with critical long-term data from a second Phase 3 trial not due until late 2026, demanding a patient, long-term outlook for any current or prospective shareholders.
• Monitor the company's planned discussions with the FDA closely, as the regulator's feedback on whether the 3.6-point MADRS reduction is sufficient for approval will be the next pivotal catalyst for the stock.